KRAS and non-small cell lung carcinoma: In oncogenic KRAS-mutated NSCLC mouse model, KRAS mutation increases the expression of Miz1, which in turn suppresses Pcdh10, leading to enhanced cell proliferation and promotion of lung tumorigenesis (Yang et al. 2022).